TY - BOOK ID - 146349537 TI - Characterization and Clinical Management of Dilated Cardiomyopathy PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Medicine KW - SCN5A KW - cardiac sodium channel KW - cardiac channelopathy KW - dilated cardiomyopathy KW - precision medicine KW - arrhythmias KW - atrial fibrillation KW - cardiomyopathy KW - heart failure KW - supraventricular arrhythmia KW - systolic dysfunction KW - tachycardiomyopathy KW - ventricular arrhythmia KW - left atrial strain KW - cardiac resynchronization therapy KW - muscular dystrophy KW - calcium KW - heart KW - gene therapy KW - phospholamban KW - Serca2a KW - mdx KW - oxidative stress KW - membrane stabilization KW - left ventricular noncompaction KW - congenital heart disease KW - congestive heart failure KW - non-ischemic cardiomyopathy KW - genetics KW - desmin KW - mitochondrial dysfunction KW - myopathy KW - whole exome sequencing KW - laminopathy KW - LMNA KW - biomarkers KW - troponin T KW - NT-proBNP KW - malignant ventricular arrhythmia KW - arrhythmic risk stratification KW - DNA methylation KW - alternative splicing KW - epigenetics KW - nonischemic dilated cardiomyopathy KW - cardiac magnetic resonance imaging KW - late gadolinium enhancement KW - long axis strain KW - left ventricle sphericity index KW - major adverse cardiovascular events KW - sex differences KW - left ventricular reverse remodelling KW - long-term outcomes KW - left ventricle non-compaction cardiomyopathy KW - cardiac magnetic resonance KW - titin KW - RNA binding motif protein 20 (RBM20) KW - sarcomere KW - diastolic dysfunction KW - phosphorylation KW - non-sense mRNA decay KW - mammalian target of rapamycin (mTOR) complex-1 KW - duchenne muscular distrophy KW - SCN5A KW - cardiac sodium channel KW - cardiac channelopathy KW - dilated cardiomyopathy KW - precision medicine KW - arrhythmias KW - atrial fibrillation KW - cardiomyopathy KW - heart failure KW - supraventricular arrhythmia KW - systolic dysfunction KW - tachycardiomyopathy KW - ventricular arrhythmia KW - left atrial strain KW - cardiac resynchronization therapy KW - muscular dystrophy KW - calcium KW - heart KW - gene therapy KW - phospholamban KW - Serca2a KW - mdx KW - oxidative stress KW - membrane stabilization KW - left ventricular noncompaction KW - congenital heart disease KW - congestive heart failure KW - non-ischemic cardiomyopathy KW - genetics KW - desmin KW - mitochondrial dysfunction KW - myopathy KW - whole exome sequencing KW - laminopathy KW - LMNA KW - biomarkers KW - troponin T KW - NT-proBNP KW - malignant ventricular arrhythmia KW - arrhythmic risk stratification KW - DNA methylation KW - alternative splicing KW - epigenetics KW - nonischemic dilated cardiomyopathy KW - cardiac magnetic resonance imaging KW - late gadolinium enhancement KW - long axis strain KW - left ventricle sphericity index KW - major adverse cardiovascular events KW - sex differences KW - left ventricular reverse remodelling KW - long-term outcomes KW - left ventricle non-compaction cardiomyopathy KW - cardiac magnetic resonance KW - titin KW - RNA binding motif protein 20 (RBM20) KW - sarcomere KW - diastolic dysfunction KW - phosphorylation KW - non-sense mRNA decay KW - mammalian target of rapamycin (mTOR) complex-1 KW - duchenne muscular distrophy UR - https://www.unicat.be/uniCat?func=search&query=sysid:146349537 AB - Dilated cardiomyopathy (DCM) is a particular phenotype of non-ischemic systolic heart failure, frequently recognizing a genetic background and affecting relatively young patients with few comorbidities. Nowadays, long-term survival of DCM patients has been markedly improved due to an early diagnosis and uninterrupted and tailored follow-up under constant optimal medical and non-pharmacological evidence-based treatments. Nevertheless, DCM is still one of the most common causes of heart transplantation in the western world. Clinical management requires an integrated and systematic use of diagnostic tools and a deeper investigation of the basic mechanisms underlying the disease. However, several emerging issues remain debated. Specifically, the genotype–phenotype correlation, the role of advanced imaging techniques and genetic testing, the lack of appropriate risk stratification models, the need for a multiparametric and multidisciplinary approach for device implantation, and a continuous reclassification of the disease during follow-up remain challenging issues in clinical practice. Therefore, the aim of this Special Issue is to shed the light on the most recent advancements in characterization and clinical management of DCM in order to unveil the conundrum of this particular disease. ER -